Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation
W R Kim, J J Poterucha, R A Jorgensen, K P Batts, H A Homburger, E R Dickson, R A Krom, R H Wiesner, K D Lindor – 30 December 2003 – Approximately 5% to 10% of patients with features otherwise consistent with primary biliary cirrhosis (PBC) lack antimitochondrial antibodies (AMA). Most of these patients have other autoantibodies, a syndrome recently named “autoimmune cholangitis.” We report our experience in patients with AMA‐negative PBC treated with ursodeoxycholic acid (UDCA) and/or liver transplantation (OLT). The study of response to UDCA was performed as follows.